Vaxart (NASDAQ:VXRT) Shares Cross Below Two Hundred Day Moving Average of $0.88

Vaxart, Inc. (NASDAQ:VXRT) passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $0.88 and traded as low as $0.63. Vaxart shares last traded at $0.66, with a volume of 1,919,722 shares traded.

Analyst Upgrades and Downgrades

Separately, B. Riley upgraded Vaxart from a “neutral” rating to a “buy” rating and set a $2.00 price objective for the company in a report on Wednesday, January 31st.

Vaxart Trading Up 7.8 %

The stock has a fifty day moving average of $1.11 and a 200-day moving average of $0.88.

Vaxart (NASDAQ:VXRT) last posted its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.03. The business had revenue of $3.25 million during the quarter, compared to the consensus estimate of $0.45 million. Vaxart had a negative return on equity of 108.45% and a negative net margin of 1,117.56%. On average, analysts anticipate that Vaxart, Inc. will post -0.45 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Kingswood Wealth Advisors LLC bought a new position in Vaxart in the first quarter valued at approximately $32,000. PFG Investments LLC bought a new position in shares of Vaxart during the 1st quarter worth approximately $38,000. AE Wealth Management LLC boosted its stake in shares of Vaxart by 180.7% during the 3rd quarter. AE Wealth Management LLC now owns 62,113 shares of the biotechnology company’s stock worth $47,000 after acquiring an additional 39,987 shares during the period. Finally, Beacon Capital Management LLC boosted its stake in shares of Vaxart by 369.9% during the 4th quarter. Beacon Capital Management LLC now owns 50,814 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 40,000 shares during the period. 18.05% of the stock is currently owned by institutional investors.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical dysplasia.